News

“This partnership is further evidence of Biogen’s ongoing commitment to multiple sclerosis and builds upon our deep experience in neuroscience and particularly in MS,” stated Michel Vounatsos, Chief Executive Officer

The new research hub will focus its research on early bioscience discovery and entrepreneurial innovation. According to MSD, by locating a research hub in London, it will be

Tagrisso is a third-generation and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity against central nervous system (CNS) metastases. It is designed to

The submission includes data from two completed trials of RUCONEST® for the prophylaxis of HAE attacks: a randomized, double-blind, placebo-controlled trial and an open-label study. The two studies

Riomet was approved in the US for the treatment of type 2 diabetes mellitus in adult and children age 10 and above. The diabetes oral solution is manufactured

KMT will become a subsidiary of PhoenixBio group effective November 30, 2017. PhoenixBio plans to invest in KMT and expand its operations. The uPA/SCID mouse model with a

Guselkumab is the first biologic that selectively blocks interleukin (IL)-23, a key driver of the immune inflammatory response in psoriasis. "We are delighted guselkumab will now be available

The trial, dubbed WISTERIA, will assess the effectiveness of the pharma company’s experimental compound AZD1775, in combination with chemotherapy prior to surgery or with chemotherapy and radiotherapy after surgery.

The VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS) is a phase 3 clinical trial of tirasemtiv in patients